Australian patients with multiple myeloma face critical shortcomings in genetic testing at diagnosis and access to new ‘standard of care’ treatments such as daratumumab, a leading haematologist has told a Parliamentary inquiry. Professor Andrew Spencer of Monash University says the current reimbursement model is unsuited to handling applications for the latest multi-agent anti-cancer treatments and ...
MM management in Australia lags behind other countries due to reimbursement model
By Michael Woodhead
17 Nov 2020